E
Adial Pharmaceuticals, Inc. ADIL
$0.69 $0.0345.18%
Recommendation
Sell
Prev Close
$0.656
Volume
39,092
Avg Vol (90D)
612,566
Market Cap
$4.31M
Dividend & Yield
--
52-Week Range
$0.614 - $3.10
P/E (TTM)
--
EPS (TTM)
-$3.48
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Adial Pharmaceuticals (NASDAQ:ADIL) Releases Quarterly Earnings Results, Beats Estimates By $0.23 EPS
3/4/2025 - Ticker Report
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update
3/4/2025 - GuruFocus
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update
3/4/2025 - Ticker Report
Adial Pharmaceuticals expects cash to fund operations into 2H of 2025
3/4/2025 - The Fly
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update
3/4/2025 - Globe Newswire
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
2/25/2025 - Globe Newswire
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach ...
2/19/2025 - GuruFocus
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies
2/19/2025 - Globe Newswire
Adial Pharmaceuticals awarded new U.S. patent on genotype-specific treatment
2/12/2025 - TipRanks Financial Blog
Adial Pharmaceuticals awarded new U.S. patent on genotype-specific treatment
2/12/2025 - The Fly
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of ...
2/12/2025 - GuruFocus
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
2/12/2025 - Globe Newswire
Adial Pharmaceuticals announce clinical study results from AD04-103 study
1/29/2025 - The Fly
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 ...
1/29/2025 - GuruFocus
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
1/29/2025 - Globe Newswire
EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder
1/29/2025 - Benzinga
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 60.8% in January
1/29/2025 - Ticker Report
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Decreases By 60.8%
1/16/2025 - Ticker Report
Adial Pharmaceuticals Highlights AD04 for Alcohol Use Disorder
1/8/2025 - TipRanks Financial Blog
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Significant Growth in Short Interest
12/31/2024 - Ticker Report
Adial Pharmaceuticals files to sell 5.0M shares of common stock for holders
12/20/2024 - The Fly
Adial Pharmaceuticals' New Purchase Agreement with Alumni Capital
12/18/2024 - TipRanks Financial Blog
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update
12/12/2024 - Ticker Report
Adial Pharmaceuticals Extends CEO Cary Claiborne's Tenure
12/6/2024 - TipRanks Financial Blog
Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence ...
12/3/2024 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$8.28M
EBIT (TTM)
-$8.28M
Net Income (TTM)
-$13.20M
Balance Sheet
Total Assets (Q)
$5.04M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$975.90K
Book Value Per Share (Q)
$0.6283
Cash Flow
Cash from Operations (TTM)
-$6.92M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$7.85M
Net Change in Cash (TTM)
$923.40K
Filings
Filing Date
Tuesday, March 4, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
1.25
7-Day Total Return
-2.82%
30-Day Total Return
-15.40%
60-Day Total Return
-36.70%
90-Day Total Return
-31.68%
Year to Date Total Return
-34.94%
1-Year Total Return
-43.90%
2-Year Total Return
-91.81%
3-Year Total Return
-98.70%
5-Year Total Return
-97.64%
52-week Low
Mar 11, 2025 - $0.614
52-week High
Apr 15, 2024 - $3.10
Valuation
Market Cap
$4.31M - Nano Cap
Enterprise Value
$562.40K
Price/Sales (TTM)
--
Price/Book (Q)
1.04
Dividends and Shares
Shares Outstanding
6.42M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.adial.com
Phone Number
(804) 487-8196
Address
4870 Sadler Road
Glen Allen, VA 23060
Country
United States
Year Founded
2010
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The... more
NASDAQ 04/02/2025 4:00PM Eastern Quotes delayed
Weiss Ratings